Here are 1-3 brief analogies for Century Therapeutics (IPSC):

• Like a more advanced version of CAR-T cell therapy companies such as Novartis or Gilead, but focusing on creating universal, 'off-the-shelf' treatments instead of patient-specific ones.
• Like a Moderna or BioNTech for cancer cell therapies, leveraging a cutting-edge iPSC platform to develop multiple 'off-the-shelf' treatments.

• CNTY-101: An allogeneic iPSC-derived CAR-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.
• CNTY-103: A CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma.
• CNTY-102: A CAR-iT candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies.
• CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate being developed for acute myeloid leukemia.
• CNTY-106: A multi-specific CAR-iNK or CAR-iT candidate being developed for multiple myeloma.

Based on the provided company description, Century Therapeutics, Inc. (IPSC) is a biotechnology company primarily focused on the research and development of transformative allogeneic cell therapies for various cancers. The company's pipeline consists of several "product candidates" (such as CNTY-101, CNTY-103, CNTY-102, CNTY-104, and CNTY-106) that are in different stages of development, including clinical trials.

As a company primarily engaged in the development of future therapies, Century Therapeutics does not currently have major customers in the traditional sense, as its products have not yet received regulatory approval and are not commercially available for sale to other companies or individual patients. Therefore, at this stage, it does not sell primarily to other companies or directly to individuals.

Brent Pfeiffenberger, PharmD, MBA President and Chief Executive Officer

Brent Pfeiffenberger was appointed President and Chief Executive Officer of Century Therapeutics, effective December 4, 2023. Prior to joining Century, he served as Chief Operating Officer of Neogene Therapeutics. He played a central role in driving Neogene's evolution from a preclinical company to a global, clinical-stage organization, ultimately culminating in its acquisition by AstraZeneca in 2023. Before Neogene, Dr. Pfeiffenberger spent nearly two decades in leadership roles of increasing responsibility at Bristol Myers Squibb, most recently as Senior Vice President, Head of U.S. Oncology, where he oversaw business operations for a multi-billion dollar franchise. He also held several critical global leadership positions where he built, led, and expanded commercial and business operations.

Morgan Conn, PhD Chief Financial Officer

Morgan Conn was appointed Chief Financial Officer of Century Therapeutics, effective October 14, 2024. He brings over 20 years of financing and business development leadership experience in biopharma. Most recently, he served as Chief Business Officer at Pharvaris, where his responsibilities included finance operations, corporate development, capital and corporate strategy, and investor relations.

Chad Cowan, PhD Chief Scientific Officer

Chad Cowan was appointed Chief Scientific Officer of Century Therapeutics, effective October 1, 2024. Prior to joining Century, Dr. Cowan was the founder and Chief Executive Officer of Clade Therapeutics, a privately-held cell therapy company focused on iPSC-derived αβ T cell programs and technology, which was acquired by Century in April 2024. He was also a scientific founder of CRISPR Therapeutics and a founder and Chief Scientific Officer of Sana Biotechnology. Earlier, he was a member of the Broad Institute and a principal faculty member of the Harvard Stem Cell Institute, where he directed the Diabetes Disease Program and the iPS Cell Core Facility.

Greg Russotti, PhD Chief Technology and Manufacturing Officer

Greg Russotti currently serves as Chief Technology and Manufacturing Officer at Century Therapeutics, a role he assumed in December 2023. He previously served as interim Chief Executive Officer from April 2023 to December 2023 and as Chief Technology Officer since January 2020. Before joining Century, Dr. Russotti was Vice President of Cell Therapy Development and Operations at Celgene. At Celgene, he guided chemistry, manufacturing, and controls efforts for five different cell therapy products to clinical-stage development. He was also a leader in establishing in-house clinical manufacturing at Celgene and in building Celgene's first commercial CAR T manufacturing facility. Prior to Celgene, Dr. Russotti spent 12 years at Merck Research Laboratories.

Key Risks to Century Therapeutics (IPSC)

1. Clinical Development and Regulatory Approval Risk: As a biotechnology company with all product candidates in development, Century Therapeutics faces significant risks related to the success of its clinical trials and the ability to obtain regulatory approvals. The failure of any lead product candidate, particularly CNTY-101, to demonstrate safety and efficacy in clinical trials, or to meet regulatory requirements, would have a material adverse impact on the company. The development of novel allogeneic, iPSC-derived cell therapies involves complex biological processes and presents unique challenges that can lead to unexpected delays or setbacks in clinical progression and regulatory pathways.
2. Intense Competition and Market Adoption: Century Therapeutics operates in a highly competitive landscape for oncology treatments, specifically in the rapidly evolving field of cell therapies for solid tumors and hematological malignancies. Other pharmaceutical and biotechnology companies, including larger, well-established players, are developing or have already commercialized CAR-T and other cell therapies. Even if its product candidates are clinically successful, Century Therapeutics will need to compete effectively based on factors such as efficacy, safety, manufacturing capabilities, and cost. Furthermore, market adoption and favorable reimbursement policies for its novel iPSC-derived therapies are critical and uncertain.
3. Manufacturing Complexity and Technology-Specific Challenges: The development and commercialization of allogeneic iPSC-derived cell therapies involve complex manufacturing processes that are difficult to scale, costly, and require specialized expertise and facilities. Any issues related to manufacturing consistency, quality control, or supply chain logistics could significantly delay product development or commercialization. Additionally, as a relatively nascent technology, the long-term safety, immunogenicity, and potential for tumorigenicity associated with iPSC-derived cells, while being actively researched and mitigated, represent inherent technological risks that could impact regulatory approval or market acceptance.

Capital Allocation Decisions for Century Therapeutics (IPSC)

Share Issuance

• Century Therapeutics launched in July 2019 with $250 million in initial financing commitments, which represented a significant share issuance to its founding investors.
• In March 2021, the company completed a $160 million Series C financing round.
• Century Therapeutics completed an oversubscribed $135 million private placement, which was reported in March 2026 to have extended its cash runway into the first quarter of 2029.

Inbound Investments

• Upon emerging from stealth mode in July 2019, Century Therapeutics secured $250 million in initial financing commitments from key partners, including Bayer, Versant Ventures, and Fujifilm Cellular Dynamics Inc. (FCDI).
• In March 2021, the company raised $160 million through a Series C financing round, led by Casdin Capital and involving a syndicate of twelve investors.
• A recent oversubscribed private placement brought in $135 million, extending Century Therapeutics' cash runway into the first quarter of 2029.

Outbound Investments

• In April 2024, Century Therapeutics acquired Clade Therapeutics for approximately $35 million in upfront consideration, paid in a mix of cash and stock, with a potential additional $10 million upon achieving a clinical milestone. This acquisition was intended to enhance Century's iPSC platform and expand its pipeline.
• In June 2020, Century Therapeutics acquired Empirica Therapeutics to leverage its expertise in iPSC-derived allogeneic cell therapies for glioblastoma (GBM).

Capital Expenditures

• In the third quarter of 2025, Century Therapeutics invested $195K in capital expenditures, primarily directed towards funding long-term assets and infrastructure.
• For the full year 2025, the company's capital expenditures amounted to $848K.